1-10 of 10
Nigel Courtenay-Luck
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract #842: Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells

Li Wang, Vijayalakshmi Sridharan, Sridharan Soundararajan, Robert Stuart, Fiona McLaughlin, Nigel Courtenay-Luck, Daniel Fernandes
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 842.
Published: 01 May 2009
View article titled, Abstract #842: Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells
Journal Articles

AS1411, a novel anti-nucleolin aptamer, shows synergy with other anti-cancer drugs in vitro and in vivo in AML models

David Jones, Donna Dobinson, Ben Doran, Tomi Odumeru, Sanne Kuijper, Christy Ritchie, Colin Green, Nigel Courtenay-Luck, Fiona McLaughlin, Hakim Djeha
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 5689.
Published: 01 May 2008
View article titled, AS1411, a novel anti-nucleolin aptamer, shows synergy with other anti-cancer drugs <em>in vitro </em>and <em>in vivo</em> in AML models
Journal Articles

The Nucleolin Targeting Aptamer AS1411 Destabilizes Bcl-2 Messenger RNA in Human Breast Cancer Cells

Sridharan Soundararajan, Weiwei Chen, Eleanor K. Spicer, Nigel Courtenay-Luck, Daniel J. Fernandes
Journal: Cancer Research
Cancer Res (2008) 68 (7): 2358–2365.
https://doi.org/10.1158/0008-5472.CAN-07-5723
Published: 01 April 2008
View article titled, The Nucleolin Targeting Aptamer AS1411 Destabilizes <em>Bcl-2</em> Messenger RNA in Human Breast Cancer Cells
Open the PDF for The Nucleolin Targeting Aptamer AS1411 Destabilizes <em>Bcl-2</em> Messenger RNA in Human Breast Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Evaluation of the potential for targeted therapy of renal carcinoma and metastatic melanoma with huBC1-huIL12 (AS1409), a potent immunocytokine

Benjamin Doran, Paul Rogers, David Jones, Colin Green, Nigel Courtenay-Luck
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 922.
Published: 01 May 2007
View article titled, Evaluation of the potential for targeted therapy of renal carcinoma and metastatic melanoma with huBC1-huIL12 (AS1409), a potent immunocytokine
Journal Articles

AS1411 inhibits the stabilization of bcl-2 mRNA by nucleolin in human breast cancer cells

Sridharan Soundararajan, Eleanor Spicer, Nigel Courtenay-Luck, Daniel Fernandes
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 4888.
Published: 01 May 2007
View article titled, AS1411 inhibits the stabilization of bcl-2 mRNA by nucleolin in human breast cancer cells
Journal Articles

Combination of the aptamer AS1411 with paclitaxel or Ara-C produces synergistic inhibition of cancer cell growth

Christy Ritchie, Benjamin Doran, Kirti Shah, Hakim Djeha, Donna Dobinson, Gail Rowlinson-Busza, Nigel Courtenay-Luck, Colin Green, David Jones
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 4818.
Published: 01 May 2007
View article titled, Combination of the aptamer AS1411 with paclitaxel or Ara-C produces synergistic inhibition of cancer cell growth
Journal Articles

Targeted delivery of interleukin 12 via an antibody specific for tumor and tumoral angiogenesis

Rakesh Verma, Yan Lan, Paul Rogers, Benjamin Doran, Christy Ritchie, David Jones, Colin Green, Scott Lauder, Stephen Gillies, Kin-Ming Lo, Lloyd R. Kelland, Nigel Courtenay-Luck
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 908.
Published: 15 April 2006
View article titled, Targeted delivery of interleukin 12 via an antibody specific for tumor and tumoral angiogenesis
Journal Articles

Combination of chemotherapy and radioimmunotherapy using 90Y-labelled anti-MUC1 humanized monoclonal antibody in a human tumor xenograft model.

Gail Rowlinson-Busza, David Griffiths-Johnson, Julie Cook, Lloyd R. Kelland, Nigel Courtenay-Luck
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 509.
Published: 01 April 2004
View article titled, Combination of chemotherapy and radioimmunotherapy using <sup>90</sup>Y-labelled anti-MUC1 humanized monoclonal antibody in a human tumor xenograft model.
Journal Articles

In vivo studies of engineered antibody-DNase I fusion proteins that target MUC1 (CD227).

Dylan M. Glubb, David Griffiths-Johnson, Rakesh Verma, Babu Dhokia, Matthew Robson, Julie Cook, Eleni Barkagianni, Lloyd R. Kelland, Nigel Courtenay-Luck, Robert J. Young
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 880.
Published: 01 April 2004
View article titled, <em>In vivo</em> studies of engineered antibody-DNase I fusion proteins that target MUC1 (CD227).
Journal Articles

HuBC1-IL12: A very potent immunocytokine which targets the oncofetal fibronectin in the extracellular matrix of tumor vasculature

Kin-Ming Lo, Yan Lan, Scott Lauder, Jinyang Zhang, Beatrice Brunkhorst, Rakesh Verma, Nigel Courtenay-Luck, Stephen D. Gillies
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 1082.
Published: 01 April 2004
View article titled, HuBC1-IL12: A very potent immunocytokine which targets the oncofetal fibronectin in the extracellular matrix of tumor vasculature